WO1997041209A1 - Pluripotent rabbit embryonic stem (es) cell lines and their use in the generation of chimeric rabbits - Google Patents
Pluripotent rabbit embryonic stem (es) cell lines and their use in the generation of chimeric rabbits Download PDFInfo
- Publication number
- WO1997041209A1 WO1997041209A1 PCT/EP1997/002323 EP9702323W WO9741209A1 WO 1997041209 A1 WO1997041209 A1 WO 1997041209A1 EP 9702323 W EP9702323 W EP 9702323W WO 9741209 A1 WO9741209 A1 WO 9741209A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- rabbit
- embryonic stem
- cell lines
- generation
- Prior art date
Links
- 241000283973 Oryctolagus cuniculus Species 0.000 title claims abstract description 65
- 210000002459 blastocyst Anatomy 0.000 claims abstract description 35
- 238000012258 culturing Methods 0.000 claims abstract description 3
- 210000004027 cell Anatomy 0.000 claims description 153
- 238000002347 injection Methods 0.000 claims description 21
- 239000007924 injection Substances 0.000 claims description 21
- 239000002609 medium Substances 0.000 claims description 17
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 16
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- 238000010186 staining Methods 0.000 claims description 11
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 8
- 238000002744 homologous recombination Methods 0.000 claims description 8
- 230000006801 homologous recombination Effects 0.000 claims description 8
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims description 8
- 210000001161 mammalian embryo Anatomy 0.000 claims description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 6
- 230000010558 Gene Alterations Effects 0.000 claims description 6
- 102000004058 Leukemia inhibitory factor Human genes 0.000 claims description 6
- 108090000581 Leukemia inhibitory factor Proteins 0.000 claims description 6
- 241001529936 Murinae Species 0.000 claims description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 6
- 239000002953 phosphate buffered saline Substances 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 6
- 230000005540 biological transmission Effects 0.000 claims description 5
- 210000004602 germ cell Anatomy 0.000 claims description 5
- 238000012546 transfer Methods 0.000 claims description 5
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 claims description 4
- 101001011741 Bos taurus Insulin Proteins 0.000 claims description 4
- 102000029816 Collagenase Human genes 0.000 claims description 4
- 108060005980 Collagenase Proteins 0.000 claims description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 4
- 241000287828 Gallus gallus Species 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 4
- 229930182816 L-glutamine Natural products 0.000 claims description 4
- 239000004107 Penicillin G sodium Substances 0.000 claims description 4
- IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 claims description 4
- 229960002424 collagenase Drugs 0.000 claims description 4
- 239000003797 essential amino acid Substances 0.000 claims description 4
- 235000020776 essential amino acid Nutrition 0.000 claims description 4
- 239000012091 fetal bovine serum Substances 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- 238000002955 isolation Methods 0.000 claims description 4
- 235000019369 penicillin G sodium Nutrition 0.000 claims description 4
- 229940056360 penicillin g Drugs 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 229960002385 streptomycin sulfate Drugs 0.000 claims description 4
- 230000024245 cell differentiation Effects 0.000 claims description 3
- 102100033421 Keratin, type I cytoskeletal 18 Human genes 0.000 claims description 2
- 108010066327 Keratin-18 Proteins 0.000 claims description 2
- 102000013127 Vimentin Human genes 0.000 claims description 2
- 108010065472 Vimentin Proteins 0.000 claims description 2
- 230000005757 colony formation Effects 0.000 claims description 2
- 210000005048 vimentin Anatomy 0.000 claims description 2
- 238000009795 derivation Methods 0.000 abstract description 9
- 238000012423 maintenance Methods 0.000 abstract description 4
- 238000005457 optimization Methods 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 210000002257 embryonic structure Anatomy 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 11
- 210000002950 fibroblast Anatomy 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- 230000004069 differentiation Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004952 blastocoel Anatomy 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 241000700159 Rattus Species 0.000 description 3
- 230000004077 genetic alteration Effects 0.000 description 3
- 231100000118 genetic alteration Toxicity 0.000 description 3
- 210000000143 trophectoderm cell Anatomy 0.000 description 3
- 206010068051 Chimerism Diseases 0.000 description 2
- 108010058936 Cohn fraction V Proteins 0.000 description 2
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000001857 anti-mycotic effect Effects 0.000 description 2
- 239000002543 antimycotic Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000010363 gene targeting Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000013011 mating Effects 0.000 description 2
- 210000000472 morula Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- 241000700112 Chinchilla Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 101000998020 Homo sapiens Keratin, type I cytoskeletal 18 Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 208000035752 Live birth Diseases 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 101000803350 Mus musculus Vimentin Proteins 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 208000035199 Tetraploidy Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000005395 beveled glass Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 230000032692 embryo implantation Effects 0.000 description 1
- 210000002242 embryoid body Anatomy 0.000 description 1
- 210000001900 endoderm Anatomy 0.000 description 1
- 210000003237 epithelioid cell Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000010196 hermaphroditism Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- LFEUVBZXUFMACD-UHFFFAOYSA-H lead(2+);trioxido(oxo)-$l^{5}-arsane Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-][As]([O-])([O-])=O.[O-][As]([O-])([O-])=O LFEUVBZXUFMACD-UHFFFAOYSA-H 0.000 description 1
- 230000004777 loss-of-function mutation Effects 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 238000002135 phase contrast microscopy Methods 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229940047883 porcine follicle stimulating hormone Drugs 0.000 description 1
- 210000005238 principal cell Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
- 210000004340 zona pellucida Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
- C12N15/877—Techniques for producing new mammalian cloned embryos
- C12N15/8777—Rabbit embryos
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/235—Leukemia inhibitory factor [LIF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/33—Insulin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
Definitions
- the present invention relates to novel rabbit embryonic stem (ES) cell lines and their use in the gene ⁇ ration of chimeric rabbits.
- Gene targeting via homologous recombination in embryonic stem (ES) cells) technology allows the manipulation of the genome in desired and defined ways (Capecchi, 1989; Robertson, 1987; Bradley, 1987) . Briefly, genes to be targeted are incorporated in plasmid transfer vectors and altered by replacement of some of their sequence with foreign DNA which encodes selectable markers (inactivation) or by a mutated gene sequence (targeted mutagenesis) . These inactivated or mutated genes are then introduced into ES cells (which each have the potential to develop into a complete animal) .
- Completely ES cell derived mice can be generated utilising the recently developed technology to aggregate wild type or mutant ES cells with tetraploid embryos (Nagy et al . , 1993) .
- ES cells can be used for introduction of genetic material by non- homologous recombination, allowing the study of genetic alteration in live animals.
- transgenic technologies and ES cell technologies for the alteration of gene function has provided animal models of important human diseases (for review cfr. Wilson, 1996; Rubin and Barsch, 1996) .
- this technology has only been successful in the mouse.
- the mouse has significant restrictions (e.g. size and inability to generate the phenotype of human diseases) that limit its potential applications. Consequently, larger animal models to test the phenotypic consequences or loss-of-function mutations would be very valuable.
- Presumptive pluripotential ES cells have been isolated in a number of additional species including hamster (Doetschman et al . , 1988) , pig (Evans et al . , 1990; Piedrahita et al . , 1990; Notarianni et al . , 1990; Talbot et al . , 1993) , sheep (Notarianni et al . , 1990) , cattle (Evans et al . ; Saito et al . , 1992) , mink (Sukoyan et al .
- Inner cell mass (ICM) cells freshly derived from rabbit blastocysts have been shown to allow the generation of chimeric rabbits following injection into recipient blastocysts (Gardner and Munro, 1974; Moustafa, 1974; Babinet and Bordenave, 1980) , whereas Yang et al . (1993) have reported the production of chimeric rabbits both from freshly isolated ICM and from ICM cells maintained in culture in vitro for 3 days.
- ES rabbit embryonic stem
- ES cell line comprising at least 70%, preferably 80 to 90% undifferentiated cells is obtainable by isolating the inner cell mass of 5.5 days postcoitus blastocysts and culturing them on feeder cells in rabbit ES medium.
- the rabbit ES medium according to the invention comprises high glucose Dulbecco' s Modified Eagle Medium, 4mM L-glutamine, 0.1 mM 2-mercaptoethanol, 148 units/ml penicillin G sodium, 148 microgram/ml streptomycin sulfate, 4 microgram/ml bovine insulin, 10 3 units/ml murine Leukemia Inhibitory Factor, 20% fetal bovine serum, 1.5% MEM non-essential amino acid solution.
- the feeder cells are preferably mouse embryonic fibroblasts derived from 12.5 days old mouse embryos and used in a density of 3 to 4X10 6 cells per 10 cm petri dish.
- a modified trypsinization method was used, which consists of the use of trypsinization medium comprising 0.1% collagenase, 1% chicken serum and 0.03% trypsin-EDTA in phosphate- buffered saline. This medium allowed the selective passage of ES cells because mouse embryonic fibroblasts and trophectodermal cells detach more slowly in this medium.
- Cells according to the invention are recognisable by virtue of their following properties: three dimensional colony formation, positive staining for alkaline phosphatase and negative staining for cytokeratin 18 and vimentin after more than 10 passages.
- the invention further relates to the use of the ES cell lines for the generation of chimeric rabbits, for example following blastocyst injection into recipient blastocysts or embryo aggregation or nuclear transfer.
- the ES cell lines of the invention may also be used for gene alteration by homologous or non-homologous recombination or for the generation of rabbits with gene alteration via germline transmission.
- the present invention thus leads to the improved derivation of pluripotent ES cells, their maintenance in culture over several passages, and their use for the successful generation of chimeric animals.
- rabbit ES cells with demonstrated potential to generate chimeric rabbits following injection in recipient blastocysts will allow the generation of offspring capable of germline transmission of the targeted mutations following homologous or non-homologous recombination in these pluripotent ES cells.
- the pluripotency of the rabbit ES cells will allow to differentiate them into defined cell types enabling the study or isolation of novel genes .
- the invention will be illustrated in the following examples, that are not intended to limit the scope of the invention. Based on the present invention, several variants and improvements will be obvious to those skilled in the art .
- the culture medium used by Graves and Moreadith (1993) consisted of high glucose Dulbecco's Modified Eagle Medium, 4mM L-glutamine, 0.1 mM 2-mercaptoethanol, penicillin G sodium l48U/ml, and streptomycin sulfate 148 ⁇ g/ml .
- the following supplements were changed or added: 4 ⁇ g/ml bovine insulin, 10 3 units/ml of murine Leukemia Inhibitory Factor, 20% fetal bovine serum, 1.5% MEM non-essential amino acid solution.
- the rabbit ES cells (1.5 to 3 X 10 6 cells per 10 cm petridish) were grown to subconfluency on mouse embryonic fibroblasts mitotically arrested with mitomycin and the ES cells were passaged every 4-6 days onto freshly prepared feeders (3 to 4 X 10 6 cells per 10 cm dish) .
- the ES cells were fed every day with the improved medium described above.
- Culture dishes were kept at 39°C in a humidified atmosphere of 5% C0 2 in air.
- the mouse embryonic fibroblast were derived from 12.5 day old mouse embryos and were used at passage 1.
- mice embryonic fibroblasts (3 to 4 X 10 6 as compared to 2 to 3 X 10 6 cells per 10 cm dish (Graves and Moreadith, 1993)) together with the use of 12.5 days' embryos markedly reduced the differentiation of the ES cells .
- the trypsinization medium consisted of 0.1% collagenase, 1% chicken serum and 0.03% trypsin-EDTA (Gibco Cat. no. 25200) in phosphate buffered saline. This selective trypsinization medium allowed the selective passage of ES cells because mouse embryonic fibroblasts and trophectodermal cells detach more slowly from the culture dish than ES cells.
- GM3 cells derived from Dutch Belted embryos by Graves and Moreadith (1993) , but maintained in culture conditions in Example 1, were used to generate chimeric offspring as described below. Blastocyst injection of the epitheloid colonies of the putative ES cells had previously never generated chimeric rabbits after injection into rabbit embryos (Table 1) . For further experiments described below, GM3 cells from passage 12 were maintained in improved culture conditions which stabilized the percentage of alkaline phosphatase positive, undifferentiated ES cells.
- Blastocysts were recovered from the uterine horns 90 hours after mating, by flushing the uterine cavity with Dulbecco' s phosphate buffered saline supplemented with 3% bovine serum albumin (Cohn fraction V) plus 5% antibiotic/antimycotic solution (Gibco, Grand Island, NY) which had been pre-equilibrated at 39°C in a humidified atmosphere of 5% C0 2 in air.
- Chimeras were generated by injection of both epitheloid alkaline phosphatase negative and the three dimensionally growing alkaline phosphatase positive ES cells into the blastocoel cavity of New Zealand White blastocyst (Table 2) .
- a total of 287 New Zealand White blastocysts were injected with 20 to 300 cells from the GM3 cell line.
- Blastocyst injections with GM3 cells were performed on a Zeiss inverted microscope with differential interference optics at a magnification of 250X. Micromanipulations were performed with Narashige micromanipulators as routinely employed for the mouse.
- Percentages in parentheses are relative to numbers of blastocysts injected.
- Superovulated Dutch Belted does were mated with Dutch Belted bucks.
- the blastocysts were flushed from the uterine horns on day 5.5 (postcoitus instead of 4 or 5 days postcoitus) and rinsed with Dulbecco' s phosphate buffered saline supplemented with 3% bovine serum albumin (Cohn fraction V) plus 5% (v/v) antibiotic/antimycotic solution.
- the blastocysts were kept in rabbit ES medium (described above) at 39°C in a 5% C0 2 incubator until further manipulation.
- the inner cell mass was prepared manually out of the surrounding trophectoderm cells with 2 needles and placed individually in a 96 well culture dish (plated with 12.5 days old, passage 1 mouse embryonic fibroblasts with a density equivalent to 3 to 4 X 10 cells per 10 cm dish) .
- the explanted inner cell masses were refed daily with the improved rabbit ES cell medium described above in which murine Leukemia Inhibitory Factor was replaced by human or rabbit Leukemia Inhibitory Factor. After 2 days, the inner cell mass outgrowth was easily freed from remaining trophectoderm cells by gently lifting the trophectoderm outgrowth with a beveled glass pipet off the underlying feeder layer and by aspirating it into the glass pipet .
- the ES cells were passaged very gradually onto larger culture dishes at 4 to 5 days intervals, to maintain the ES cells at a very high density, another prerequisite to prevent differentiation and loss of pluripotency.
- the feeder densities on the subsequent culture dishes was maintained at densities equivalent of 3 to 4 X 10 cells per 10 cm dish.
- the rabbit ES cell lines obtained by this procedure are more similar to pluripotent murine ES cell lines than any of the rabbit ES variants previously reported.
- the main characteristics are colony growth in three dimensions, high refractility and a small nuclear/cytoplasmic ratio. The most important characteristics are that after 10 passages, 80 to 90% of the ES cells remain undifferentiated as indicated by their positive staining for alkaline phosphatase ( Figure 3b) , and negative staining for human cytokeratin 18 and mouse vimentin, which are known markers of differentiation (Viebahn et al . , 1988; Piedrahita et al . , 1990) .
- Roder JC (1993) Derivation of completely cell culture derived mice from early-passage embryonic stem cells Proc Natl Acad Sci USA 90:8424-8428.
- Strojeck M, Reed MA, Hoover JL, Wagner TE (1990) A method for cultivating morphologically undifferentiated embryonic stem cells from porcine blastocysts. Theriogenology 33:901-913.
- Rabbit ES cells (GM3 line) , derived by Graves and Moreadith.
- the belts are typical for the Dutch Belted strain from which the GM3 ES cell line was derived.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Developmental Biology & Embryology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Gynecology & Obstetrics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Reproductive Health (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU28929/97A AU2892997A (en) | 1996-04-29 | 1997-04-29 | Pluripotent rabbit embryonic stem (es) cell lines and their use in the generation of chimeric rabbits |
EP97922992A EP0907722A1 (en) | 1996-04-29 | 1997-04-29 | Pluripotent rabbit embryonic stem (es) cell lines and their use in the generation of chimeric rabbits |
JP9538604A JP2000508919A (en) | 1996-04-29 | 1997-04-29 | Pluripotent rabbit embryonic stem (ES) cell line and its use in developing chimeric rabbits |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP96201169.8 | 1996-04-29 | ||
EP96201169 | 1996-04-29 | ||
EP96203060 | 1996-11-04 | ||
EP96203060.7 | 1996-11-04 | ||
EP97200168 | 1997-01-22 | ||
EP97200168.9 | 1997-01-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997041209A1 true WO1997041209A1 (en) | 1997-11-06 |
Family
ID=27237546
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1997/002323 WO1997041209A1 (en) | 1996-04-29 | 1997-04-29 | Pluripotent rabbit embryonic stem (es) cell lines and their use in the generation of chimeric rabbits |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0907722A1 (en) |
JP (1) | JP2000508919A (en) |
CN (1) | CN1217746A (en) |
AU (1) | AU2892997A (en) |
CA (1) | CA2252524A1 (en) |
WO (1) | WO1997041209A1 (en) |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999027076A1 (en) * | 1997-11-25 | 1999-06-03 | Arc Genomic Research | Pluripotent embryonic stem cells and methods of obtaining them |
US6238922B1 (en) * | 1999-02-26 | 2001-05-29 | Stemcells, Inc. | Use of collagenase in the preparation of neural stem cell cultures |
WO2001044441A1 (en) * | 1999-12-14 | 2001-06-21 | Thermo Biostar, Inc. | Stabilizing diluent for polypeptides and antigens |
US6271436B1 (en) | 1996-10-11 | 2001-08-07 | The Texas A & M University System | Cells and methods for the generation of transgenic pigs |
EP1217071A1 (en) | 2000-12-22 | 2002-06-26 | Institut National De La Recherche Agronomique (Inra) | Position-independent and tissue specific expression of a transgene in milk of transgenic animals |
EP1294855A1 (en) * | 2000-06-20 | 2003-03-26 | ES Cell International Pte Ltd | Method of controlling differentiation of embryonic stem (es) cells by culturing es cells in the presence of bmp-2 pathway antagonists |
AU762112B2 (en) * | 1997-11-25 | 2003-06-19 | Arc Genomic Research | Pluripotent embryonic stem cells and methods of obtaining them |
FR2834518A1 (en) * | 2002-01-10 | 2003-07-11 | Agronomique Inst Nat Rech | METHOD FOR NUCLEAR CLONING IN RABBITS AND USES |
US7312078B2 (en) | 1998-02-17 | 2007-12-25 | Gamida Cell Ltd. | Methods of controlling proliferation and differentiation of stem and progenitor cells |
US7344881B2 (en) | 2002-01-25 | 2008-03-18 | Gamida Cell Ltd. | Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby |
US8846393B2 (en) | 2005-11-29 | 2014-09-30 | Gamida-Cell Ltd. | Methods of improving stem cell homing and engraftment |
US9149026B2 (en) | 2010-06-11 | 2015-10-06 | Regeneron Pharmaceuticals, Inc. | Production of fertile XY animals from XY ES cells |
US9175266B2 (en) | 2012-07-23 | 2015-11-03 | Gamida Cell Ltd. | Enhancement of natural killer (NK) cell proliferation and activity |
US9499790B2 (en) | 2010-08-26 | 2016-11-22 | Kyoto University | Method for promoting differentiation of pluripotent stem cells into cardiac muscle cells |
US9567569B2 (en) | 2012-07-23 | 2017-02-14 | Gamida Cell Ltd. | Methods of culturing and expanding mesenchymal stem cells |
US9587220B2 (en) | 2012-01-27 | 2017-03-07 | Kyoto University | Method for inducing cardiac differentiation of pluripotent stem cell |
US10047345B2 (en) | 2012-02-13 | 2018-08-14 | Gamida-Cell Ltd. | Culturing of mesenchymal stem cells with FGF4 and nicotinamide |
US10196609B2 (en) | 2013-03-08 | 2019-02-05 | Kyoto University | Composition for promoting cardiac differentiation of pluripotent stem cell comprising EGFR inhibitor |
US10233426B2 (en) | 2014-05-30 | 2019-03-19 | Kyoto University | Method for inducing cardiac differentiation of pluripotent stem cell with low-molecular compounds |
US10793874B2 (en) | 2014-06-26 | 2020-10-06 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for targeted genetic modifications and methods of use |
US10893666B2 (en) | 2015-09-17 | 2021-01-19 | Regeneron Pharmaceuticals, Inc. | Production of fertile XY female animals by silencing of genes on the Y chromosome |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5807862B2 (en) * | 2009-12-01 | 2015-11-10 | 国立研究開発法人国立がん研究センター | Preparation of chimeric rat using rat embryonic stem cells |
WO2011071118A1 (en) | 2009-12-09 | 2011-06-16 | 国立大学法人京都大学 | Agent for promoting differentiation of pluripotent stem cells into cardiac muscle cells which includes nitrovin |
JP5930205B2 (en) | 2010-08-26 | 2016-06-08 | 国立大学法人京都大学 | Promoting myocardial differentiation of pluripotent stem cells |
JP6333830B2 (en) | 2013-09-13 | 2018-05-30 | 国立大学法人京都大学 | Compounds that promote myocardial differentiation of pluripotent stem cells |
JP6970446B2 (en) | 2016-03-18 | 2021-11-24 | 国立大学法人京都大学 | Method of freezing aggregates of pluripotent stem cell-derived cardiomyocytes |
CN109609446B (en) * | 2018-11-14 | 2020-11-03 | 广西大学 | A kind of culture medium and method for separating and culturing rabbit embryonic stem cells |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990001541A1 (en) * | 1988-08-04 | 1990-02-22 | Amrad Corporation Limited | In vitro propagation of embryonic stem cells |
WO1994026884A1 (en) * | 1993-05-14 | 1994-11-24 | Biotechnology Research And Development Corporation | Embryonic stem cells for making chimeric and transgenic ungulates |
-
1997
- 1997-04-29 JP JP9538604A patent/JP2000508919A/en active Pending
- 1997-04-29 AU AU28929/97A patent/AU2892997A/en not_active Abandoned
- 1997-04-29 CA CA002252524A patent/CA2252524A1/en not_active Abandoned
- 1997-04-29 WO PCT/EP1997/002323 patent/WO1997041209A1/en not_active Application Discontinuation
- 1997-04-29 EP EP97922992A patent/EP0907722A1/en not_active Withdrawn
- 1997-04-29 CN CN97194183A patent/CN1217746A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990001541A1 (en) * | 1988-08-04 | 1990-02-22 | Amrad Corporation Limited | In vitro propagation of embryonic stem cells |
WO1994026884A1 (en) * | 1993-05-14 | 1994-11-24 | Biotechnology Research And Development Corporation | Embryonic stem cells for making chimeric and transgenic ungulates |
Non-Patent Citations (6)
Title |
---|
"METHODS IN ENZYMOLOGY", 1979, ACADEMIC PRESS, XP002026376 * |
DU F. ET AL: "Nuclear transfer of putative rabbit embryonic stem cells leads to normal blastocyst development", JOURNAL OF REPRODUCTION AND FERTILITY, vol. 104, 1995, pages 219 - 223, XP000645112 * |
GILES J.R. ET AL: "Pluripotency of cultured rabbit inner cell mass cells detected by isozyme analysis and eye pigmentation of fetuses following injection into blastocysts or morulae", MOLECULAR REPRODUCTION AND DEVELOPMENT, vol. 36, 1993, pages 130 - 138, XP000645165 * |
GRAVES K.H. ET AL: "Derivation and characterization of putative pluripotential embryonic stem cells from preimplantation rabbit embryos", MOLECULAR REPRODUCTION AND DEVELOPMENT, vol. 36, 1993, pages 424 - 433, XP000645113 * |
SCHOONJANS L. ET AL: "Pluripotential rabbit embryonic stem (ES) cells are capable of forming overt coat color chimeras following injection into blastocysts", MOLECULAR REPRODUCTION AND DEVELOPMENT, vol. 45, December 1996 (1996-12-01), pages 439 - 443, XP000645114 * |
STROJEK R.M. ET AL: "A method for cultivating morphologically undifferentiated embryonic stem cells from porcine blastocytes", THERIOGENOLOGY, vol. 33, no. 4, 1990, pages 901 - 913, XP002026375 * |
Cited By (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6271436B1 (en) | 1996-10-11 | 2001-08-07 | The Texas A & M University System | Cells and methods for the generation of transgenic pigs |
US6369294B1 (en) | 1996-10-11 | 2002-04-09 | Texas A&M University System | Methods comprising apoptosis inhibitors for the generation of transgenic pigs |
AU762112B2 (en) * | 1997-11-25 | 2003-06-19 | Arc Genomic Research | Pluripotent embryonic stem cells and methods of obtaining them |
WO1999027076A1 (en) * | 1997-11-25 | 1999-06-03 | Arc Genomic Research | Pluripotent embryonic stem cells and methods of obtaining them |
US7312078B2 (en) | 1998-02-17 | 2007-12-25 | Gamida Cell Ltd. | Methods of controlling proliferation and differentiation of stem and progenitor cells |
US7429489B2 (en) | 1998-09-29 | 2008-09-30 | Gamida Cell Ltd. | Methods of controlling proliferation and differentiation of stem and progenitor cells |
US7049141B1 (en) | 1999-02-26 | 2006-05-23 | Stemcells California, Inc. | Use of collagenase in the preparation of neural stem cell cultures |
US6238922B1 (en) * | 1999-02-26 | 2001-05-29 | Stemcells, Inc. | Use of collagenase in the preparation of neural stem cell cultures |
US6579688B2 (en) | 1999-12-14 | 2003-06-17 | Biostar, Inc. | Stabilizing diluent for polypeptides and antigens |
WO2001044441A1 (en) * | 1999-12-14 | 2001-06-21 | Thermo Biostar, Inc. | Stabilizing diluent for polypeptides and antigens |
US9080147B2 (en) | 2000-06-20 | 2015-07-14 | Es Cell International Pte Ltd. | Culturing human embryonic stem cells with a noggin to generate cells lacking Pax-6 expression |
EP1294855A4 (en) * | 2000-06-20 | 2004-09-15 | Es Cell Int Pte Ltd | Method of controlling differentiation of embryonic stem (es) cells by culturing es cells in the presence of bmp-2 pathway antagonists |
EP2298867A3 (en) * | 2000-06-20 | 2013-01-16 | ES Cell International Pte Ltd. | Method of controlling differentiation of embryonic stem (ES) cells by culturing ES cells in the presence of bmp-2 pathway antagonists |
EP1294855A1 (en) * | 2000-06-20 | 2003-03-26 | ES Cell International Pte Ltd | Method of controlling differentiation of embryonic stem (es) cells by culturing es cells in the presence of bmp-2 pathway antagonists |
EP1217071A1 (en) | 2000-12-22 | 2002-06-26 | Institut National De La Recherche Agronomique (Inra) | Position-independent and tissue specific expression of a transgene in milk of transgenic animals |
EP2138583A1 (en) | 2000-12-22 | 2009-12-30 | Institut National De La Recherche Agronomique | Position-independent and tissue specific expression of a transgene in milk of transgenic animals |
WO2003059053A3 (en) * | 2002-01-10 | 2004-04-01 | Agronomique Inst Nat Rech | Rabbit nuclear cloning method and uses thereof |
WO2003059053A2 (en) * | 2002-01-10 | 2003-07-24 | Institut National De La Recherche Agronomique | Rabbit nuclear cloning method and uses thereof |
FR2834518A1 (en) * | 2002-01-10 | 2003-07-11 | Agronomique Inst Nat Rech | METHOD FOR NUCLEAR CLONING IN RABBITS AND USES |
US7344881B2 (en) | 2002-01-25 | 2008-03-18 | Gamida Cell Ltd. | Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby |
US8846393B2 (en) | 2005-11-29 | 2014-09-30 | Gamida-Cell Ltd. | Methods of improving stem cell homing and engraftment |
US9398762B2 (en) | 2010-06-11 | 2016-07-26 | Regeneron Pharmaceuticals, Inc. | Production of fertile XY female animals from XY ES cells |
US9885058B2 (en) | 2010-06-11 | 2018-02-06 | Regeneron Pharmaceuticals, Inc. | Production of fertile XY female mice from XY mouse ES cells |
US9149026B2 (en) | 2010-06-11 | 2015-10-06 | Regeneron Pharmaceuticals, Inc. | Production of fertile XY animals from XY ES cells |
US9655351B2 (en) | 2010-06-11 | 2017-05-23 | Regeneron Pharmaceuticals, Inc. | Production of fertile XY female animals from XY ES cells |
US9499790B2 (en) | 2010-08-26 | 2016-11-22 | Kyoto University | Method for promoting differentiation of pluripotent stem cells into cardiac muscle cells |
US9587220B2 (en) | 2012-01-27 | 2017-03-07 | Kyoto University | Method for inducing cardiac differentiation of pluripotent stem cell |
US10047345B2 (en) | 2012-02-13 | 2018-08-14 | Gamida-Cell Ltd. | Culturing of mesenchymal stem cells with FGF4 and nicotinamide |
US9567569B2 (en) | 2012-07-23 | 2017-02-14 | Gamida Cell Ltd. | Methods of culturing and expanding mesenchymal stem cells |
US9175266B2 (en) | 2012-07-23 | 2015-11-03 | Gamida Cell Ltd. | Enhancement of natural killer (NK) cell proliferation and activity |
US10196609B2 (en) | 2013-03-08 | 2019-02-05 | Kyoto University | Composition for promoting cardiac differentiation of pluripotent stem cell comprising EGFR inhibitor |
US10233426B2 (en) | 2014-05-30 | 2019-03-19 | Kyoto University | Method for inducing cardiac differentiation of pluripotent stem cell with low-molecular compounds |
US10793874B2 (en) | 2014-06-26 | 2020-10-06 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for targeted genetic modifications and methods of use |
US10893666B2 (en) | 2015-09-17 | 2021-01-19 | Regeneron Pharmaceuticals, Inc. | Production of fertile XY female animals by silencing of genes on the Y chromosome |
US12041918B2 (en) | 2015-09-17 | 2024-07-23 | Regeneron Pharmaceuticals, Inc. | Production of fertile XY female animals by silencing of genes on the Y chromosome |
Also Published As
Publication number | Publication date |
---|---|
AU2892997A (en) | 1997-11-19 |
CN1217746A (en) | 1999-05-26 |
EP0907722A1 (en) | 1999-04-14 |
CA2252524A1 (en) | 1997-11-06 |
JP2000508919A (en) | 2000-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1997041209A1 (en) | Pluripotent rabbit embryonic stem (es) cell lines and their use in the generation of chimeric rabbits | |
Schoonjans et al. | Pluripotential rabbit embryonic stem (ES) cells are capable of forming overt coat color chimeras following injection into blastocysts | |
US10039269B2 (en) | Methods and compositions for generating a mouse | |
Ledermann et al. | Establishment of a germ-line competent C57BL/6 embryonic stem cell line | |
Wheeler | Development and validation of swine embryonic stem cells: a review | |
Hong et al. | Pluripotency and differentiation of embryonic stem cell lines from the medakafish (Oryzias latipes) | |
US6436701B1 (en) | Derivation of pluripotential embryonic cell lines from ungulate species | |
Strelchenko | Bovine pluripotent stem cells | |
Dattena et al. | Isolation, culture, and characterization of embryonic cell lines from vitrified sheep blastocysts | |
Sukoyan et al. | Establishment of new murine embryonic stem cell lines for the generation of mouse models of human genetic diseases | |
US6103523A (en) | Pluripotent rabbit cell lines and method of making | |
Anderson | Isolation and use of embryonic stem cells from livestock species | |
KR101213691B1 (en) | Preantral Follicle-Derived Embryonic Stem Cells | |
Mizutani et al. | Propagation of senescent mice using nuclear transfer embryonic stem cell lines | |
Zhou et al. | In vitro derivation of germ cells from embryonic stem cells in mammals | |
Modliński et al. | Embryonic stem cells: developmental capabilities and their possible use in mammalian embryo cloning | |
US20070250943A1 (en) | Construction of Chimera Using En Cells | |
EP0716690A1 (en) | Rat pluripotent embryonic stem cells and method of obtaining and using same | |
Peli et al. | Comparison of aggregation and injection techniques in producing chimeras with embryonic stem cells in mice | |
Strelchenko | Bovine Pluripotent stem cells for transgenic vectors | |
KR100250599B1 (en) | H3 embryonic stem cell line and process for preparing a transgenic mouse by using same | |
US20030124720A1 (en) | Conditioned culture media | |
Kim et al. | Factors Affecting the Productivity of Germ-line Chimeras from Jl Embryonic Stem Cells | |
Panasophonkul et al. | Establishment of porcine embryonic stem-like cells from parthenogenetic and in vivo derived embryos | |
CN119300848A (en) | Chimeric ovarian follicle-based therapy for female infertility |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 97194183.1 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2252524 Country of ref document: CA Ref document number: 2252524 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997922992 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1997922992 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997922992 Country of ref document: EP |